IGF::OT::IGF A Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a candidate broadly protective vaccine for the prevention of HPV-associated cancer

University Of Wisconsin-Madison, Madison WI

Investigators

Abstract

Develop and conduct a phase 1 safety and immunogenicity trial of HPV16L1-16RG1 VLP Vaccine in healthy 27?45-year-old women at three escalating doses.